254 related articles for article (PubMed ID: 16243811)
1. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53 overexpression in endometrial cancer.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
[TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma.
Saito S; Ito K; Nagase S; Suzuki T; Akahira J; Okamura K; Yaegashi N; Sasano H
Cancer Sci; 2006 Dec; 97(12):1308-14. PubMed ID: 16999816
[TBL] [Abstract][Full Text] [Related]
5. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
7. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
Suzuki T; Urano T; Miki Y; Moriya T; Akahira J; Ishida T; Horie K; Inoue S; Sasano H
Cancer Sci; 2007 May; 98(5):644-51. PubMed ID: 17359284
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas.
Segawa T; Sasagawa T; Saijoh K; Inoue M
Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
11. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
Powell MA; Mutch DG; Rader JS; Herzog TJ; Huang TH; Goodfellow PJ
Cancer; 2002 Jun; 94(11):2941-52. PubMed ID: 12115383
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
13. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Salvesen HB; Das S; Akslen LA
Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
Engelsen IB; Stefansson IM; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2008 Nov; 199(5):543.e1-7. PubMed ID: 18599012
[TBL] [Abstract][Full Text] [Related]
15. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
20. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
